You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RIGL quote. I consider RIGL to be a strong buy based on Tavalisse revenue growth , expense reductions pushing the company towards breakeven, existing clinical catalysts and Rezlidhia’s potential to add to revenues. With RIGL at current prices you have a biotech with a market cap of ~$200M, net sales heading towards $100M annually, pushing to profitability with clinical catalysts ahead. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Rigel Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings. A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. Results from the COVID-19 trial of fostamatinib are still possible in 2023, with the clinicaltrials.gov entry for the ACTIV-4 study being updated on February 23 with an estimated primary completion date of August 29, 2023. I think investors can hope for some more details on RIGL’s expected expenses and revenues to get a clearer picture on RIGL’s push towards breakeven and profitability with Q1’23 earnings.
7 Wall Street analysts have issued 12 month target prices for Rigel Pharmaceuticals’ stock. Their RIGL share price forecasts range from $1.00 to $15.00. On average, they anticipate the company’s share price to reach $4.21 in the next year. This suggests a possible upside of 275.7% from the stock’s current price. View analysts price targets for RIGL or view top-rated stocks among Wall Street analysts.
The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Updated interim analysis from Phase 2 registrational study highlights 35% of mIDH1 R/R AML patients who received olutasidenib achieved CR+CRh with a median duration of 25.9 months Presentations across… REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML patie… It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations.
Outside of product sales there is the potential for an upfront payment from a partner if RIGL partners Rezlidhia, giving up ex-US revenues, or partners Rezlidhia in new indications outside of r/r AML. The Chief Commercial Officer of RIGL, Dave Santos, also mentioned one of the challenges in marketing Rezlidhia, noting that half the potential prescribers are more difficult to access. We’re seeing a small increase actually in patients — bottles shipped to patients and clinics.
Recently Viewed Tickers
Only 13 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Rigel Pharmaceuticals does not have a long track record of dividend growth. Measures how much net income or profit is generated as a percentage of revenue.
Rigel Pharmaceuticals, Inc. (RIGL)
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
While there are some questions worth addressing on 10 qualities of a successful entrepreneur‘s cash balance, the company is pushing towards breakeven and potentially profitability. RIGL is set to report Q1’23 earnings on Tuesday, May 2, with the stock currently trading around year-to-date lows. Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Oil & Gas, Basic Materials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Industrials, Oil & Gas and Basic Materials sectors propelled shares higher. Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Basic Materials, Utilities and Industrials sectors propelled shares lower.
Rezlidhia was approved on December 1, 2022, in certain relapsed/refractory acute myeloid leukemia patients (r/r AML) with an IDH1 mutation, and only became commercially available on December 22, 2022. As such, Rezlidhia’s net product sales of $0.9M in Q4’22 were never going to be huge. A total of 64 bottles were shipped to distributors, with two shipped on to patients and clinics in Q4’22. FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE® net product sales of $19.2 million and total revenues of $22.4 million Conference call and … We sell different types of products and services to both investment professionals and individual investors.
At the very least we’ll have more clarity on revenue growth with Tavalisse (such as confirming the strong Q1’23 to which the CEO alluded), and the launch of Rezlidhia. Outside of sales of Tavalisse and Rezlidhia, or upfront payments from partnering Rezlidhia or R289, RIGL also has the potential to bring in milestone payments from its existing collaborators. RIGL is also considering partnering R289, the company’s IRAK1/4 inhibitor, which is currently in a trial in patients with myelodysplastic syndromes . Still the CCO did say the company was making progress in that regard and so with Q1’23 earnings we might expect some confirmation that the company has continued to make strides to reach the target prescribers.
Rigel Pharmaceuticals stock price target raised to $7 from $6 at J.P. Morgan
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms.
As we’ve talked about, there are about a 1,000 AML prescribers that we’ve — we’re calling on as targets. About half of those are consistent with our TAVALISSE targets and about half of those are leukemia treaters, who really are specialized in leukemia. And those are the people that can be more difficult to access, and it’s been a little bit more difficult for us…
Rigel Pharmaceuticals has a short interest ratio (“days to cover”) of 2.9, which is generally considered an acceptable ratio of short interest to trading volume. Rigel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. According to analysts’ consensus price target of $4.21, Rigel Pharmaceuticals has a forecasted upside of 275.7% from its current price of $1.12. Represents the company’s profit divided by the outstanding shares of its common stock. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
- Secondly, disappointing results in any of RIGL’s clinical trials could see the stock trade down.
- 7 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Rigel Pharmaceuticals in the last year.
- CompareRIGL’s historical performanceagainst its industry peers and the overall market.
- Firstly, Rezlidhia sales could underwhelm even if there is growth quarter-over-quarter.
- This is a decrease of -63% compared to the previous 30 days.
The firm’s lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE tablets, the only oral spleen tyrosine kinase inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor. REZLIDHIA™ U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation Preliminary fourth quarter 2022 Total Revenue of a…
Just to remind you, last https://1investing.in/ Q4 was our best quarter since launch, given that we are seeing some growth on top of that. This Q1 will be our best quarter since launch, not our best quarter first quarter, our best quarter since launch. Storylines Follow Bloomberg reporters as they uncover some of the biggest financial crimes of the modern era. This documentary-style series follows investigative journalists as they uncover the truth. Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Utilities, Consumer Goods and Oil & Gas sectors propelled shares lower. By Oliver Gray Investing.com – U.S. stock futures were little changed on Tuesday, after a negative session among major benchmark averages as investors retreated following Federal Reserve…
Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 7 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Rigel Pharmaceuticals in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “hold” RIGL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RIGL, but not buy additional shares or sell existing shares.
It’s calculated by multiplying the current market price by the total number of shares outstanding. Shares of Rigel Pharmaceuticals Inc. soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. Even then, if RIGL expected no new milestone payments from collaborators in 2023, the company can reduce its expenses more aggressively. Firstly, RIGL could cut R&D expense by halting trials, such as the company’s efforts with its IRAK1/4 inhibitor, R289, in myelodysplastic syndromes. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. RIGL, +1.86% soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia tr… According to 7 analysts, the average rating for RIGL stock is “Buy.” The 12-month stock price forecast is $4.38, which is an increase of 282.53% from the latest price. Incrementally in January, we received $20 million from Kissei.
- Shares of Rigel Pharmaceuticals Inc. soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment.
- So we’re comfortable with our current cash position in the business that we’ve discussed today.
- Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
- Verify your identity, personalize the content you receive, or create and administer your account.
Raul Rodriguez has an approval rating of 84% among the company’s employees. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter. 73.88% of the stock of Rigel Pharmaceuticals is held by institutions.